ReviewHuman vaccines & immunotherapeutics2014
Recent advances in oral vaccine development: yeast-derived β-glucan particles.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Oral delivery of Trichinella spiralis antigens by yeast-derived β-glucan particles enhances anti-helminth immunity.NPJ vaccines · 2026Article
- Oral yeast-displayed SARS-CoV-2 spike protein vaccine enhanced by trimerization and flagellin peptide.Scientific reports · 2026Article
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Fungal β-Glucans: Biological Properties, Immunomodulatory Effects, Diagnostic and Therapeutic Applications.Infectious diseases & clinical microbiology · 2025Review
- RecombinantApplied and environmental microbiology · 2025Article
- Article
- Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024Review
- Understanding yeast shells: structure, properties and applications.ADMET & DMPK · 2024Review
- Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics · 2023Review
- RNA Vaccines: Yeast as a Novel Antigen Vehicle.Vaccines · 2023Review
- Oral Vaccines: A Better Future of Immunization.Vaccines · 2023Review
- Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.Journal of nanobiotechnology · 2023Review
- Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery.Pharmacological reports : PR · 2022Review
- Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants.Clinical and experimental vaccine research · 2022Review
- Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.Microbiology spectrum · 2022Article
- Bile acid linked β-glucan nanoparticles for liver specific oral delivery of biologics.Biomaterials science · 2022Article
- Estimating & comparing greenhouse gas emissions for existing intramuscular COVID-19 vaccines and a novel thermostable oral vaccine.The journal of climate change and health · 2022Article
- Oral Immunogenicity of EnterotoxigenicPharmaceutics · 2022Article
- Oral Delivery of SARS-CoV-2 DNA Vaccines Using AttenuatedMolecular genetics, microbiology and virology : Molekulyarnaya genetika, mikrobiologiya i virusologiya · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral vaccination is the most challenging vaccination method due to the administration route. However, oral vaccination has socio-economic benefits and provides the possibility of stimulating both humoral and cellular immune responses at systemic and mucosal sites. Despite the advantages of oral vaccination, only a limited number of oral vaccines are currently approved for human use. During the last decade, extensive research regarding antigen-based oral vaccination methods have improved immunogenicity and induced desired immunological outcomes. Nevertheless, several factors such as the harsh gastro-intestinal environment and oral tolerance impede the clinical application of oral delivery systems. To date, human clinical trials investigating the efficacy of these systems are still lacking. This review addresses the rationale and key biological and physicochemical aspects of oral vaccine design and highlights the use of yeast-derived β-glucan microparticles as an oral vaccine delivery platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.